Nicotine replacement therapy (NRT) includes a variety of products like patches, gums, lozenges, inhalers, and nasal sprays that help taper nicotine intake for those attempting to quit smoking and other tobacco products. As the health risks of smoking have become more well-known in recent decades due to scientific research, more smokers are motivated to quit. NRT products have proven effective as they release nicotine gradually over time to help relieve cravings and withdrawal symptoms during the initial quitting process without many of the harmful toxins found in cigarette smoke. While willpower alone is still the primary method for smokers to quit, NRT provides an additional evidence-based option that has helped millions of people on their journey toward becoming smoke-free.
Market Dynamics:
The global nicotine replacement therapy market is driven by the rising prevalence of smoking-related diseases and growing awareness about the health risks of tobacco use. However, the market also faces some restraints from the availability of cheaper alternatives to NRT products like e-cigarettes. There is an opportunity for market players to invest in developing more innovative nicotine delivery methods and combination NRT therapies for different lifestyles. Countries with large smoking populations and expanding healthcare systems also present significant market potential. For instance, on May 4, 2023, according to a report published by the Centers for Disease Control and Prevention, in 2021, an estimated 11.5% (28.3 million) of the U.S. adults smoked cigarettes, due to which there was more than US$ 240 billion loss in healthcare spending and nearly US$ 372 billion productivity was lost.
Key Features of the Study:
- This report provides an in-depth analysis of the global nicotine replacement therapy market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nicotine replacement therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Johnson & Johnson Inc. , Haleon Group of Companies, Imperial Brands plc, Cipla Inc., Pfizer Inc., GLENMARK PHARMACEUTICALS LTD, Fertin Pharma, Philip Morris Products S.A., British American Tobacco plc, Japan Tobacco Inc., Habitrol., Perrigo Company plc, Die betapharm Arzneimittel GmbH, ITC Limited , Sparsha Pharma International Pvt Ltd, and Alkalon A/S
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nicotine replacement therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nicotine replacement therapy market
Detailed Segmentation:
- Global Nicotine Replacement Therapy Market, By Product Type
- Inhalers
- Gum
- Transdermal Patches
- Sublingual Tablets
- Lozenges
- Others
- Global Nicotine Replacement Therapy Market, By Distribution Channel
- Global Nicotine Replacement Therapy Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Global Nicotine Replacement Therapy Market, Key Players
- Johnson & Johnson Inc. *
- Haleon Group of Companies
- Imperial Brands plc
- Cipla Inc.
- Pfizer Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fertin Pharma
- Philip Morris Products S.A.
- British American Tobacco plc
- Japan Tobacco Inc.
- Perrigo Company plc
- Die betapharm Arzneimittel GmbH
- ITC Limited
- Sparsha Pharma International Pvt Ltd
- Alkalon A/S